Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Vicore Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension

Contact the Supplier

Lead Product(s): VP01

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VP01

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Administration of clinically relevant oral doses of VP01 in the so called Sugen-Hypoxia-induced pulmonary hypertension model in rats caused a significant and therapeutically meaningful reduction in pulmonary arterial pressure without affecting the systemic blood pressure.